MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	5/16/2005 8:03:02 AM
	Read Replies (1) of 1826

MGI Pharma "outperform" Monday, May 16, 2005 6:52:13 AM ET Robert W. Baird NEW YORK, May 16 (newratings.com) - Analysts at Robert W Baird maintain their "outperform" rating on MGI Pharma Inc (MOGN.NAS). The target price is set to $35. In a research note published this morning, the analysts mention that the company's Dacogen drug is currently under regulatory review in the US and the EU. Robert W Baird expresses its optimism regarding the prospects of MGI Pharma's Dacogen drug, in view of the recent encouraging efficacy data for the drug’s MDS dosing trial. Dacogen is likely to be approved in 2005, the analysts say.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next